Evaxion Biotech A/S (EVAX) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Evaxion Biotech A/S

EVAX

NASDAQ

Unprofitable

521116

Biotechnology

Next Earning date - 27 May 2025

521116

Biotechnology

Next Earning date - 27 May 2025

1.65USD

0.06 ( 3.77%)

Market Closed (as of Apr 25, 20:00 EDT)

Relative Strenght

Volume Buzz

-95%

Earning Acce

Dist 52w H.

92%

Overview Chart

Quote Panel

Updated April 28, 2025

1W 20.44 % 1M -10.81 % 3M -51.33 % 1Y -92.31 %

Key Metrics

Market Cap
521116
Shares Outstanding
315829
Share in Float
286632
Dividende
0

Earning Date
27 May 2025
Price Target
1.65
Average Volume
1.29M
Beta
-0.247

Range
1.2-21.55
Industry
Biotechnology
Website
https://www.evaxion-biotech.com
Sector
Healthcare

Quote Panel

Updated April 28, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.16x

P/S Ratio

-0.37x

P/B Ratio

-6.1

Debt/Equity

-315.2%

Net Margin

$-10.0

EPS

How EVAX compares to sector?

P/E Ratio

Fundamentals

Relative Strength

EVAX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

EVAX

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$4M

2902%

2025-Revenue

$1.83

81%

2025-EPS

$733K

113%

2025-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-14.50
vs -12.50

Q2.23

N/A

-10.50
vs -10.00

Q3.23

N/A

-10.50
vs NA

Q4.23

N/A

-0.80
vs -0.39

Q1.24

+101%

0.15
vs -14.50

Q2.24

N/A

-0.60
vs -10.50

Q3.24

N/A

-0.20
vs -10.50

Q4.24

N/A

-0.80
vs -0.80

Q1.25

N/A

-0.70
vs 0.15

Q2.25

N/A

-0.52
vs -0.60

Sales Growth

YoY

Current

Estimates

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

73.6K vs NA

Q1.24

50.9K vs NA

Q2.24

153.9K vs NA

Q3.24

3M vs NA

Q4.24

+66%

122K vs 73.6K

Q1.25

+18%

60K vs 50.9K

Q2.25

-59%

62.5K vs 153.9K

Return on Equity

QoQ

Q1.23

+8%

0.08
vs 0.09

Q2.23

-224%

-2.24
vs 0.08

Q3.23

+6%

0.06
vs -2.24

Q4.23

+96%

0.96
vs 0.06

Q1.24

+46%

0.46
vs 0.96

Q2.24

-494%

-4.94
vs 0.46

Q3.24

-2623%

-26.23
vs -4.94

Q4.24

+220%

2.2
vs -26.23

Institutionnal Ownership

QoQ

Q1.22

14
vs 15

-7%

Q2.22

11
vs 14

-21%

Q3.22

9
vs 11

-18%

Q4.22

11
vs 9

22%

Q1.23

11
vs 11

Q2.23

10
vs 11

-9%

Q3.23

11
vs 10

10%

Q4.23

10
vs 11

-9%

Earnings Growth

Latest News

globenewswire.com

8 hours ago

Evaxion to present at World Vaccine Congress

globenewswire.com

8 hours ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

globenewswire.com

8 hours ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

seekingalpha.com

11 hours ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

globenewswire.com

16 hours ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

globenewswire.com

16 hours ago

Evaxion announces closing of $10.8 million public offering

Company Description

1.65USD

N/A

0.16x

-0.37x

-6.1

-315.2%

$-10.0

$4M

$1.83

$733K

Earnings Growth

Latest News

Company Description

1.65USD

N/A

0.16x

-0.37x

-6.1

-315.2%

$-10.0